| Dr Ashwin Ananth, MD | |
|
1851 N Mckenzie St Ste 106, Foley, AL 36535-4704 | |
| (251) 943-1117 | |
| Not Available |
| Full Name | Dr Ashwin Ananth |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 9 Years |
| Location | 1851 N Mckenzie St Ste 106, Foley, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447644570 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YS0012X | Otolaryngology - Sleep Medicine | MD.42784 (Alabama) | Primary |
| 207Y00000X | Otolaryngology | 01090539A (Indiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thomas Hospital | Fairhope, AL | Hospital |
| Deaconess Hospital Inc | Evansville, IN | Hospital |
| South Baldwin Regional Medical Center | Foley, AL | Hospital |
| Mobile Infirmary Medical Center | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Shore Ear, Nose And Throat Clinic, Pc | 2769405877 | 4 |
| Deaconess Clinic Inc | 3375610116 | 337 |
News Archive
Hythiam, Inc. (NASDAQ:HYTM) announced today that on September 15, 2009, the Company received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold as set forth in NASDAQ Listing Rule 5450(a)(1) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement.
All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep's therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.
The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.
Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay.
Eleven Patient Research Partners (PRPs) from three organizations (EULAR, GRAPPA-EU, and EUROPSO) participate in the new research project HIPPOCRATES, ensuring the patients' perspective is preserved and prioritized in all research activities to maximize the project's impact.
› Verified 8 days ago
| Entity Name | Eastern Shore Ear, Nose & Throat Clinic, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386707339 PECOS PAC ID: 2769405877 Enrollment ID: O20060104000374 |
News Archive
Hythiam, Inc. (NASDAQ:HYTM) announced today that on September 15, 2009, the Company received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold as set forth in NASDAQ Listing Rule 5450(a)(1) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement.
All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep's therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.
The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.
Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay.
Eleven Patient Research Partners (PRPs) from three organizations (EULAR, GRAPPA-EU, and EUROPSO) participate in the new research project HIPPOCRATES, ensuring the patients' perspective is preserved and prioritized in all research activities to maximize the project's impact.
› Verified 8 days ago
| Entity Name | Ent Centers Of Excellence |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689043515 PECOS PAC ID: 2860702891 Enrollment ID: O20151103003103 |
News Archive
Hythiam, Inc. (NASDAQ:HYTM) announced today that on September 15, 2009, the Company received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold as set forth in NASDAQ Listing Rule 5450(a)(1) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement.
All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep's therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.
The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.
Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay.
Eleven Patient Research Partners (PRPs) from three organizations (EULAR, GRAPPA-EU, and EUROPSO) participate in the new research project HIPPOCRATES, ensuring the patients' perspective is preserved and prioritized in all research activities to maximize the project's impact.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ashwin Ananth, MD 1851 N Mckenzie St Ste 106, Foley, AL 36535-4704 Ph: (251) 943-1117 | Dr Ashwin Ananth, MD 1851 N Mckenzie St Ste 106, Foley, AL 36535-4704 Ph: (251) 943-1117 |
News Archive
Hythiam, Inc. (NASDAQ:HYTM) announced today that on September 15, 2009, the Company received a letter from The NASDAQ Stock Market indicating that because the bid price of the Company's common stock had closed below the minimum $1.00 per share threshold as set forth in NASDAQ Listing Rule 5450(a)(1) for the prior 30 consecutive business days, the Company has been provided 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement.
All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep's therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.
The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.
Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA® PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay.
Eleven Patient Research Partners (PRPs) from three organizations (EULAR, GRAPPA-EU, and EUROPSO) participate in the new research project HIPPOCRATES, ensuring the patients' perspective is preserved and prioritized in all research activities to maximize the project's impact.
› Verified 8 days ago
Dr. John L Pallin, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1628 N Mckenzie St, Foley, AL 36535 Phone: 251-943-2470 Fax: 251-943-1949 | |
Fred G Fedok, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 113 E Fern Ave, Foley, AL 36535 Phone: 251-943-6003 Fax: 251-943-2429 |